Skip to content

Study · In vitro (cells) · 2023

1 result

Enantiomeric Virus-Inspired Oncolytic Particles for Efficient Antitumor Immunotherapy.

Li Y, Deng K, Shen C, Liang X, Zeng Z, Liu L, Xu X

ACS nano28 Jul 2023Cited by 22 (Europe PMC)

PMID37506386 (opens in a new tab)DOI10.1021/acsnano.3c05288 (opens in a new tab)PepBankPUB-37506386
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In cell tests, LTX‑315 had a cytotoxicity IC50 of 53.00 μg mL-1.

    In plain wordsIn cells, LTX‑315 had a reported cytotoxicity IC50.

    Peptide
    LTX-315
    Outcome
    Not applicableCytotoxicity IC50
    Study

    n: not reported in source

    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Measurements

    IC50
    53 μg mL-1
    LTX-315

    Source sentences

    Summary
    clinical-grade oncolytic agents (LTX-315, IC50 = 53.00 μg mL-1)

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.